What Is Somatropin Used For? Approved Uses, Per the Label

Somatropin is a prescription medicine in the United States. It is recombinant human growth hormone, produced by biotechnology methods so that its amino acid sequence matches pituitary-derived human growth hormone, and it is supplied as an injectable product under several brand names. This page summarises what somatropin is approved for according to US prescribing information, describes the trial evidence commonly associated with each indication, and notes the regulatory history of the product class. It does not give dosing directions and does not tell any reader what to do.

This page is for educational purposes only and is not medical advice; consult a licensed physician or prescribing clinician about whether any approved indication applies to a particular person.

How Somatropin Labels Are Organised

Somatropin is marketed in the United States by more than one manufacturer, and each brand carries its own prescribing information. The brands do not all carry the same indications. A product such as Norditropin (somatropin) injection, Novo Nordisk, lists a set of pediatric indications plus adult growth hormone deficiency; other somatropin brands, including Genotropin, Humatrope, Omnitrope, Nutropin AQ, Saizen, Serostim and Zorbtive, each carry their own indication list, and two of those, Serostim and Zorbtive, are approved for adult conditions that are not growth disorders at all.

Because of this, the accurate answer to "what is somatropin used for" is always brand-specific. A clinician prescribing somatropin works from the indication section of the specific product label and its current revision. Readers checking a specific brand and revision year should consult the current prescribing information for that product, since indications and label revisions change over time.

Pediatric Indications in Somatropin Labelling

Growth failure due to inadequate endogenous growth hormone secretion

The founding indication for somatropin is treatment of pediatric patients with growth failure due to inadequate secretion of endogenous growth hormone. This indication dates back to the era when growth hormone was extracted from human pituitary glands; recombinant somatropin replaced pituitary-derived material in the mid-1980s after the pituitary-derived product was withdrawn because of Creutzfeldt-Jakob disease transmission.

The largest body of outcome data in this indication comes from long-running observational registries. Researchers analysing the full KIGS cohort, an international pediatric growth hormone registry, reported growth outcomes and safety data across the pooled pediatric population treated with growth hormone, including children with growth hormone deficiency, and the authors characterised the overall safety profile of pediatric growth hormone therapy in that cohort (PMID 36102184).

Daily somatropin has also served as the active comparator in the registration trials of newer long-acting growth hormone products, which indirectly documents its effect on growth. A phase 3 study compared weekly somatrogon with daily somatropin in children with growth hormone deficiency and reported annual height velocity as the primary endpoint in that comparison (PMID 35405011). The enliGHten extension trial reported two-year efficacy and safety results for lonapegsomatropin in children with growth hormone deficiency, in a development programme in which daily somatropin served as the comparator arm (PMID 35428884).

Turner syndrome

Several somatropin labels include treatment of short stature associated with Turner syndrome in patients whose epiphyses are not closed. This indication was added in the 1990s and is present across multiple brands. Registry data covering treated pediatric populations, including Turner syndrome, were summarised in the full KIGS cohort analysis (PMID 36102184).

Prader-Willi syndrome

Somatropin labelling in the United States includes treatment of pediatric patients with growth failure due to Prader-Willi syndrome, confirmed by appropriate genetic testing. Labels for this indication carry a prominent contraindication relating to severely obese patients and those with severe respiratory impairment, following reports of fatal outcomes in that subgroup. The KIGS registry analysis reported safety data across the treated pediatric population including syndromic indications (PMID 36102184).

Small for gestational age with failure to catch up

Labels include treatment of growth failure in children born small for gestational age who fail to manifest catch-up growth by a specified age. This indication was added to US somatropin labelling in the early 2000s, after European approval of the same indication.

Idiopathic short stature

Idiopathic short stature, defined in labelling as short stature without an identified cause in patients with open epiphyses who are unlikely to attain a normal adult height, was added to US somatropin labelling in 2003. It is one of the most debated indications in the class because the underlying condition is a statistical definition rather than a hormone deficiency. Pooled registry safety data for the treated pediatric population were reported in the KIGS cohort analysis (PMID 36102184).

SHOX deficiency

Short stature homeobox-containing gene (SHOX) deficiency appears as an indication on some somatropin labels, covering short stature in patients with confirmed SHOX gene haploinsufficiency whose epiphyses are not closed. This indication was added in the later 2000s and is not carried by every brand.

Noonan syndrome

Short stature associated with Noonan syndrome appears on some somatropin labels. A two-year randomised, double-blind, multicentre trial in Japanese patients evaluated two doses of Norditropin (somatropin) in short stature due to Noonan syndrome and reported efficacy and safety outcomes for both dose groups (PMID 29109363). That trial is among the controlled data sets supporting the Noonan syndrome indication.

Chronic kidney disease

Some somatropin labels include growth failure associated with chronic kidney disease, generally up to the time of renal transplantation. Pediatric nephrology populations were among those represented in the registry safety analysis of pediatric growth hormone therapy (PMID 36102184).

Adult Indications in Somatropin Labelling

Adult growth hormone deficiency

Somatropin labelling includes replacement of endogenous growth hormone in adults with growth hormone deficiency of either adult onset or childhood onset, where the deficiency is confirmed by appropriate testing. This indication was added to US labelling in the mid-1990s and shifted the drug from a purely pediatric growth product to a hormone replacement product.

A review of long-term efficacy and safety of somatropin for adult growth hormone deficiency summarised the body composition, metabolic and safety outcomes described in extended treatment studies in this population (PMID 15871547). More recent work in the same indication examined what happens when patients already established on treatment are switched to a long-acting analogue: researchers reported metabolic and muscular outcomes in adults with growth hormone deficiency who switched from somatropin to somapacitan (PMID 41955533).

HIV-associated wasting or cachexia

The somatropin product marketed as Serostim carries an indication for the treatment of HIV patients with wasting or cachexia, to increase lean body mass and body weight and improve physical endurance. This indication was granted in 1996 during the period when antiretroviral therapy was less effective at preventing wasting, and it remains a distinct adult indication within the somatropin class.

Short bowel syndrome

The somatropin product marketed as Zorbtive carries an indication for the treatment of short bowel syndrome in patients receiving specialised nutritional support. This indication was granted in 2003. A pharmacotherapy review of somatropin for short bowel syndrome in adults summarised the trial data and the clinical rationale that supported use of growth hormone with nutritional support in this population (PMID 16086660).

Indication Summary Table

Regulatory History of the Indication Set

1. Recombinant somatropin entered US practice in the mid-1980s for pediatric growth hormone deficiency, replacing pituitary-derived growth hormone.
2. Through the 1990s, indications expanded to chronic kidney disease growth failure, Turner syndrome, adult growth hormone deficiency and HIV-associated wasting.
3. The 2000s added Prader-Willi syndrome, small for gestational age, idiopathic short stature, short bowel syndrome, SHOX deficiency and Noonan syndrome, with the specific list varying by brand.
4. Follow-on somatropin products were approved under US pathways that compare a new product with an approved reference product. Reviews of biosimilar science describe how analytical characterisation, pharmacokinetic comparison and immunogenicity assessment are used to support such approvals (PMID 29284760), and a pharmacology review reported that changes in manufacturing processes for biologic therapies can alter the immunogenicity profile of a product (PMID 31628764).
5. From 2021, long-acting growth hormone products entered the same pediatric indication space. Lonapegsomatropin received its first approval for pediatric growth hormone deficiency, as described in a regulatory profile of that product (PMID 34709591), and a 2023 update reviewed the long-acting growth hormone class and its development programmes (PMID 37842029).

Adverse Events in the Approved Populations: What Studies Report

Safety information belongs with the indication it was gathered in. Researchers reporting the full KIGS cohort described the safety profile of pediatric growth hormone therapy across the registry population and reported on adverse events captured during long-term follow-up (PMID 36102184). In adults, a review of long-term somatropin treatment for adult growth hormone deficiency summarised the safety findings reported in extended treatment studies (PMID 15871547).

Injection-site findings have been described for growth hormone products in pediatric practice. A case series reported reversible injection-site lipoatrophy induced by the long-acting growth hormone somatrogon in children treated for growth hormone deficiency (PMID 41261869). In the Noonan syndrome trial, the investigators reported efficacy and safety outcomes for both dose groups over two years (PMID 29109363). Immunogenicity is a standing consideration for recombinant protein products, and a pharmacology review reported that manufacturing process changes can alter a biologic product's immunogenicity profile (PMID 31628764).

One Note on Uses Outside the Label

Somatropin is sometimes discussed in contexts outside the approved indications listed above, including anti-ageing, athletic and body composition contexts. Those are not approved uses, they are not described in this page as uses, and US law places specific restrictions on distribution of human growth hormone for purposes other than approved indications. Questions about whether any approved indication applies to an individual belong with a prescribing clinician.

What the Evidence Base Does and Does Not Settle

The indication list reflects regulatory decisions made over nearly four decades, each based on the evidence available at the time for that specific population. Controlled trials such as the two-year Noonan syndrome study reported efficacy and safety for the population enrolled (PMID 29109363), while registry work such as the full KIGS cohort analysis reported outcomes across a far broader and less selected treated population (PMID 36102184). Newer comparative trials, including the phase 3 weekly somatrogon versus daily somatropin study (PMID 35405011) and the enliGHten two-year lonapegsomatropin results (PMID 35428884), position daily somatropin as the established comparator in pediatric growth hormone deficiency. None of this determines what is appropriate for any individual, which is a decision for a licensed prescribing clinician working from the current label of the specific product.

References

• Lonapegsomatropin: Pediatric First Approval (Paediatric Drugs, 2022)
• Efficacy and safety of two doses of Norditropin (somatropin) in short stature due to Noonan syndrome: a 2-year randomized, double-blind, multicenter trial in Japanese patients (Endocrine Journal, 2018)
• Safety and Efficacy of Pediatric Growth Hormone Therapy: Results From the Full KIGS Cohort (The Journal of Clinical Endocrinology and Metabolism, 2022)
• Efficacy and Safety of Weekly Somatrogon vs Daily Somatropin in Children With Growth Hormone Deficiency: A Phase 3 Study (The Journal of Clinical Endocrinology and Metabolism, 2022)
• Long acting growth hormone (LAGH), an update (Frontiers in Pediatrics, 2023)
• Somatropin for the treatment of short bowel syndrome in adults (Expert Opinion on Pharmacotherapy, 2005)
• Reversible Injection-Site Lipoatrophy Induced by Long-Acting Growth Hormone (Somatrogon) in Pediatric Growth Hormone Deficiency: A Case Series (Journal of Clinical Research in Pediatric Endocrinology, 2025)
• Long-term efficacy and safety of somatropin for adult growth hormone deficiency (Treatments in Endocrinology, 2003)
• Safety and Efficacy of Lonapegsomatropin in Children With Growth Hormone Deficiency: enliGHten Trial 2-Year Results (The Journal of Clinical Endocrinology and Metabolism, 2022)
• Metabolic and muscular effects of switching from somatropin to somapacitan in adults with growth hormone deficiency (The Journal of Clinical Endocrinology and Metabolism, 2026)
• Changes in Manufacturing Processes of Biologic Therapies Can Alter the Immunogenicity Profile of the Product (Clinical Pharmacology and Therapeutics, 2020)
• The Concept of Biosimilars: From Characterization to Evolution, A Narrative Review (The Oncologist, 2018)